A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 Gangliosidoses, and Ataxia Telangiectasia
View ORCID ProfileT. Fields, View ORCID ProfileM. Patterson, View ORCID ProfileT. Bremova, G. Belcher, I. Billington, View ORCID ProfileG.C. Churchill, W. Davis, W. Evans, S. Flint, View ORCID ProfileA. Galione, U. Granzer, J. Greenfield, R. Karl, R. Kay, D. Lewi, T. Mathieson, T. Meyer, D. Pangonis, View ORCID ProfileF.M. Platt, L. Tsang, C. Verburg, M. Factor, View ORCID ProfileM. Strupp
doi: https://doi.org/10.1101/2020.03.11.20034256
T. Fields
1IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford OX5 1PF, United Kingdom
M. Patterson
2Mayo Clinic, 200 First Street SW, Rochester MN 55905, United States
T. Bremova
3Department of Neurology, Inselspital, University Hospital Bern, and University of Bern, Bern, Switzerland
G. Belcher
4PV Consultancy, 113 St Georges Square Mews, London SW1V 3RZ, United Kingdom
I. Billington
1IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford OX5 1PF, United Kingdom
G.C. Churchill
5Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, United Kingdom
W. Davis
6Ataxia-Telangiectasia Society, Rothamsted Experimental Station West Common, Harpenden AL5 2JQ, United Kingdom
W. Evans
7Niemann-Pick UK, Suite 2, Vermont House, Concord, Washington, Tyne and Wear, NE37 2SQ; Primary Care Stratified Medicine (PRISM), Division of Primary Care, University of Nottingham, Nottingham
S. Flint
1IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford OX5 1PF, United Kingdom
A. Galione
5Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, United Kingdom
U. Granzer
8Granzer Regulatory Consulting & Services, Kistlerhofstr. 172C, D-81379 München, Germany
J. Greenfield
9Ataxia UK, 12 Broadbent close, London N6 5JW, United Kingdom
R. Karl
10Cure Tay-Sachs Foundation 2409 E. Luke Avenue, Phoenix AZ, 85016, Unites States
R. Kay
11RK Statistics, Brook House, Mesne Lane, Bakewell DE45 1AL, United Kingdom
D. Lewi
12The Cure & Action for Tay-Sachs (CATS) Foundation, 94 Milborough Crescent, Lee, London SE12 0RW, United Kingdom
T. Mathieson
13International Niemann-Pick Disease Alliance, Suite 2, Vermont House, Concord, Washington, Tyne and Wear, NE37 2SQ, United Kingdom
T. Meyer
8Granzer Regulatory Consulting & Services, Kistlerhofstr. 172C, D-81379 München, Germany
D. Pangonis
14National Tay-Sachs and Allied Disease Foundation; 2001 Beacon Street, Suite 204, Boston, MA 02135, United States
F.M. Platt
5Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, United Kingdom
L. Tsang
15Arnold & Porter Kaye Scholer LLP, 25 Old Broad Street | London EC2N 1HQ, United Kingdom
C. Verburg
1IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford OX5 1PF, United Kingdom
M. Factor
1IntraBio Ltd, Begbroke Science Park, Begroke Hill, Woodstock Road, Oxford OX5 1PF, United Kingdom
M. Strupp
16Department of Neurology and German Center for Vertigo and Balance Disorders, Ludwig Maximilians University, Munich, Germany
Article usage
Posted March 20, 2020.
A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 Gangliosidoses, and Ataxia Telangiectasia
T. Fields, M. Patterson, T. Bremova, G. Belcher, I. Billington, G.C. Churchill, W. Davis, W. Evans, S. Flint, A. Galione, U. Granzer, J. Greenfield, R. Karl, R. Kay, D. Lewi, T. Mathieson, T. Meyer, D. Pangonis, F.M. Platt, L. Tsang, C. Verburg, M. Factor, M. Strupp
medRxiv 2020.03.11.20034256; doi: https://doi.org/10.1101/2020.03.11.20034256
A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 Gangliosidoses, and Ataxia Telangiectasia
T. Fields, M. Patterson, T. Bremova, G. Belcher, I. Billington, G.C. Churchill, W. Davis, W. Evans, S. Flint, A. Galione, U. Granzer, J. Greenfield, R. Karl, R. Kay, D. Lewi, T. Mathieson, T. Meyer, D. Pangonis, F.M. Platt, L. Tsang, C. Verburg, M. Factor, M. Strupp
medRxiv 2020.03.11.20034256; doi: https://doi.org/10.1101/2020.03.11.20034256
Subject Area
Subject Areas
- Addiction Medicine (313)
- Allergy and Immunology (616)
- Anesthesia (158)
- Cardiovascular Medicine (2256)
- Dermatology (201)
- Emergency Medicine (368)
- Epidemiology (11547)
- Forensic Medicine (10)
- Gastroenterology (676)
- Genetic and Genomic Medicine (3541)
- Geriatric Medicine (336)
- Health Economics (611)
- Health Informatics (2286)
- Health Policy (910)
- Hematology (333)
- HIV/AIDS (742)
- Medical Education (357)
- Medical Ethics (100)
- Nephrology (385)
- Neurology (3324)
- Nursing (190)
- Nutrition (504)
- Oncology (1747)
- Ophthalmology (522)
- Orthopedics (208)
- Otolaryngology (283)
- Pain Medicine (222)
- Palliative Medicine (66)
- Pathology (435)
- Pediatrics (998)
- Primary Care Research (399)
- Public and Global Health (5971)
- Radiology and Imaging (1216)
- Respiratory Medicine (807)
- Rheumatology (367)
- Sports Medicine (311)
- Surgery (383)
- Toxicology (50)
- Transplantation (170)
- Urology (142)